AR066576A1 - Nuevos derivados de pirazolona - Google Patents
Nuevos derivados de pirazolonaInfo
- Publication number
- AR066576A1 AR066576A1 ARP080102055A ARP080102055A AR066576A1 AR 066576 A1 AR066576 A1 AR 066576A1 AR P080102055 A ARP080102055 A AR P080102055A AR P080102055 A ARP080102055 A AR P080102055A AR 066576 A1 AR066576 A1 AR 066576A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- dione
- group
- alkyl
- thiomorpholin
- Prior art date
Links
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- -1 pyrrolidin-2,5-dione-1-yl Chemical group 0.000 abstract 5
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Substances 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
Inhibidores efectivos de la fosfodiesterasa tipo 4, sus composiciones farmacéuticas y usos para tratar enfermedades respiratorias. Reivindicacion 1: Un compuesto caracterizado porque es de formula 1: en donde R1 representa un derivado fenilo deformula (2) o (3) en donde R2 se selecciona del grupo que consiste en alcoxi C1-2 y alcoxi C1-2 que está completa o predominantemente sustituido por fluor; R3 se selecciona del grupo que consiste en alcoxi C1-2, cicloalcoxi C3-5, cicloalquilmetoxiC3-5 y alcoxi C1-2 que está completa o predominantemente sustituido por fluor; R4 se selecciona del grupo que consiste en alcoxi C1-2, y alcoxi C1-2-alcoxi que está completa o predominantemente sustituido por fluor; RS es alquilo C1-2 y R6 seselecciona del grupo que consiste en hidrogeno y alquilo C1-2; o R5 y R6 juntos y con inclusion de los dos átomos de carbono a los cuales están enlazados, forman un anillo de hidrocarburo de 5 o 6 miembros de enlace espiro; R7 es alquilo C1-3 y R8es alquilo C1-3, o R7 y R8 juntos con el átomo de carbono al cual están enlazados, forman un anillo hidrocarburo de 3, 4, 5 o 6 miembros de enlace espiro, R9 es -N(R11)R12, en donde R11 y R12 juntos y con inclusion del átomo de nitrogeno al cualestán enlazados, forman un anillo heterocíclico seleccionado del grupo que consiste en un anillo pirrolidin-2,5-diona-1-ilo, isoindol-1,3-diona-2-ilo, 2-oxo-2,3-dihidro-1H-indol-1-ilo, pirrolidin-2-ona-lilo, piperidin-2,6-diona-1-ilo, morfolin-3,5-diona-4-ilo, tiomorfolin-3,5-diona-4-ilo, tiomorfolin-1-oxido-3,5-diona-4-ilo y a tiomorfolin-1,1-dioxido-3,5-diona-4-ilo; y n es 1 o 2; o un estereoisomero del compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108314 | 2007-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066576A1 true AR066576A1 (es) | 2009-08-26 |
Family
ID=38179942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102055A AR066576A1 (es) | 2007-05-16 | 2008-05-15 | Nuevos derivados de pirazolona |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8304436B2 (es) |
| EP (3) | EP2402330B1 (es) |
| JP (2) | JP5529010B2 (es) |
| KR (1) | KR101601284B1 (es) |
| CN (2) | CN101657441B (es) |
| AR (1) | AR066576A1 (es) |
| AT (1) | ATE526326T1 (es) |
| AU (1) | AU2008250069B2 (es) |
| BR (1) | BRPI0811214A2 (es) |
| CA (1) | CA2686909C (es) |
| CO (1) | CO6220956A2 (es) |
| CY (1) | CY1112152T1 (es) |
| DK (1) | DK2148876T3 (es) |
| EA (1) | EA018984B1 (es) |
| EC (1) | ECSP099738A (es) |
| ES (2) | ES2427442T3 (es) |
| HR (1) | HRP20110940T1 (es) |
| IL (1) | IL201959A (es) |
| ME (1) | ME00952B (es) |
| MX (1) | MX2009012062A (es) |
| MY (1) | MY154498A (es) |
| NZ (1) | NZ581547A (es) |
| PL (1) | PL2148876T3 (es) |
| PT (1) | PT2148876E (es) |
| RS (1) | RS52074B (es) |
| SI (1) | SI2148876T1 (es) |
| TW (2) | TWI414521B (es) |
| UA (1) | UA100019C2 (es) |
| WO (1) | WO2008138939A1 (es) |
| ZA (1) | ZA200906423B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008138939A1 (en) * | 2007-05-16 | 2008-11-20 | Nycomed Gmbh | Pyrazolone derivatives as pde4 inhibitors |
| AR074318A1 (es) * | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
| WO2010101246A1 (ja) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
| WO2011136752A1 (en) * | 2010-04-26 | 2011-11-03 | Mahmut Bilgic | Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases |
| JP5609614B2 (ja) * | 2010-12-15 | 2014-10-22 | 東ソー株式会社 | 新規アリールアミンデンドリマー状化合物、その製造方法およびその用途 |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2903460A (en) * | 1956-04-07 | 1959-09-08 | Sandoz Ag | Pyrazolone derivatives |
| US4550119A (en) | 1983-05-23 | 1985-10-29 | Warner-Lambert Company | 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones |
| IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
| PL307265A1 (en) | 1992-07-28 | 1995-05-15 | Rhone Poulenc Rorer Ltd | Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom |
| PL178314B1 (pl) | 1993-07-02 | 2000-04-28 | Byk Gulden Lomberg Chem Fab | Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy |
| RU2138498C1 (ru) | 1994-07-22 | 1999-09-27 | Бык Гульден Ломберг Хемише Фабрик Гмбх | Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе |
| SI0971901T1 (en) * | 1997-01-15 | 2003-10-31 | Altana Pharma Ag | Phthalazinones |
| US6418201B1 (en) | 2000-02-22 | 2002-07-09 | Intel Corporation | Multiple platform voice processing system with optimized resource allocation |
| CZ20032491A3 (cs) | 2001-02-15 | 2004-01-14 | Altana Pharma Ag | Ftalazinonpiperidinové deriváty |
| PT1383733E (pt) | 2001-04-20 | 2008-04-15 | Pfizer Prod Inc | Processo para a preparação de indenos 1,3-substituídos e compostos azapolicíclicos fundidos com arilo |
| JP2004526789A (ja) | 2001-04-25 | 2004-09-02 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規フタラジノン |
| WO2004018451A1 (en) * | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
| AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| EP1556049A1 (en) | 2002-08-10 | 2005-07-27 | ALTANA Pharma AG | Piperidine-pyridazones and phthalazones as pde4 inhibitors |
| EP1539801B1 (en) * | 2002-08-20 | 2015-03-25 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
| US7825147B2 (en) * | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
| EP1720854A1 (en) * | 2004-02-04 | 2006-11-15 | Altana Pharma AG | Phthalzinone derivatives as pde4 inhibitors |
| EP1716133B1 (en) * | 2004-02-04 | 2008-03-26 | Nycomed GmbH | 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors |
| JP2006169138A (ja) * | 2004-12-14 | 2006-06-29 | Kyorin Pharmaceut Co Ltd | ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤 |
| WO2008138939A1 (en) * | 2007-05-16 | 2008-11-20 | Nycomed Gmbh | Pyrazolone derivatives as pde4 inhibitors |
-
2008
- 2008-05-14 WO PCT/EP2008/055867 patent/WO2008138939A1/en not_active Ceased
- 2008-05-14 CA CA2686909A patent/CA2686909C/en not_active Expired - Fee Related
- 2008-05-14 CN CN2008800119475A patent/CN101657441B/zh not_active Expired - Fee Related
- 2008-05-14 SI SI200830491T patent/SI2148876T1/sl unknown
- 2008-05-14 AT AT08759563T patent/ATE526326T1/de active
- 2008-05-14 EP EP11182678.0A patent/EP2402330B1/en active Active
- 2008-05-14 JP JP2010507909A patent/JP5529010B2/ja not_active Expired - Fee Related
- 2008-05-14 KR KR1020097025745A patent/KR101601284B1/ko not_active Expired - Fee Related
- 2008-05-14 ES ES11182678T patent/ES2427442T3/es active Active
- 2008-05-14 HR HR20110940T patent/HRP20110940T1/hr unknown
- 2008-05-14 US US12/451,348 patent/US8304436B2/en not_active Expired - Fee Related
- 2008-05-14 DK DK08759563.3T patent/DK2148876T3/da active
- 2008-05-14 RS RS20110570A patent/RS52074B/sr unknown
- 2008-05-14 UA UAA200912770A patent/UA100019C2/uk unknown
- 2008-05-14 NZ NZ581547A patent/NZ581547A/en not_active IP Right Cessation
- 2008-05-14 MY MYPI20094317A patent/MY154498A/en unknown
- 2008-05-14 MX MX2009012062A patent/MX2009012062A/es active IP Right Grant
- 2008-05-14 PL PL08759563T patent/PL2148876T3/pl unknown
- 2008-05-14 CN CN201310349480.8A patent/CN103463086B/zh not_active Expired - Fee Related
- 2008-05-14 AU AU2008250069A patent/AU2008250069B2/en not_active Ceased
- 2008-05-14 ME MEP-2009-327A patent/ME00952B/me unknown
- 2008-05-14 EP EP12174018A patent/EP2508520A1/en not_active Withdrawn
- 2008-05-14 ES ES08759563T patent/ES2374337T3/es active Active
- 2008-05-14 PT PT08759563T patent/PT2148876E/pt unknown
- 2008-05-14 BR BRPI0811214-2A2A patent/BRPI0811214A2/pt active Search and Examination
- 2008-05-14 EP EP08759563A patent/EP2148876B1/en active Active
- 2008-05-14 EA EA200901504A patent/EA018984B1/ru not_active IP Right Cessation
- 2008-05-15 AR ARP080102055A patent/AR066576A1/es not_active Application Discontinuation
- 2008-05-16 TW TW097118165A patent/TWI414521B/zh not_active IP Right Cessation
- 2008-05-16 TW TW102129216A patent/TWI460174B/zh not_active IP Right Cessation
-
2009
- 2009-09-15 ZA ZA200906423A patent/ZA200906423B/xx unknown
- 2009-10-16 CO CO09115665A patent/CO6220956A2/es active IP Right Grant
- 2009-11-05 IL IL201959A patent/IL201959A/en not_active IP Right Cessation
- 2009-11-13 EC EC2009009738A patent/ECSP099738A/es unknown
-
2011
- 2011-12-20 CY CY20111101261T patent/CY1112152T1/el unknown
-
2012
- 2012-09-14 US US13/618,026 patent/US8865745B2/en not_active Expired - Fee Related
-
2014
- 2014-04-16 JP JP2014084704A patent/JP5850972B2/ja not_active Expired - Fee Related
- 2014-08-29 US US14/473,338 patent/US9090597B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066576A1 (es) | Nuevos derivados de pirazolona | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR066881A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| AR066120A1 (es) | Derivados de pirimidinona y sus metodos de uso | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR066882A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR078884A1 (es) | Antagonistas del receptor crth2 basados en indol | |
| AR049139A1 (es) | Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii. | |
| BRPI0907122B8 (pt) | compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR077849A2 (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
| AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR045955A1 (es) | Compuestos benzoimidazolicos | |
| AR059901A1 (es) | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. | |
| PE20091425A1 (es) | Derivados de aminotiazol | |
| AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |